A $175 million settlement has been reached and is pending approval in the antitrust class action lawsuit filed regarding the company's nonsteroidal anti-inflammatory product Relafen. (Feb-06-04) [GSK]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no obligation, please fill in our form on the right to submit your complaint.

Add Your Comment on This Issue

Please read our comment guidelines before posting.

Note: Your name will be published with your comment.

Your email will only be used if a response is needed.

Request Legal Help